

For those patients who should avoid taking nonselective ocular beta blockers...

“Most patients for whom timolol is prescribed are elderly, and disorders likely to be aggravated by beta-adrenergic-receptor blocking agents are common in this age group.”¹

When there is a chance of developing cardiopulmonary problems, such as bronchial asthma or heart failure, which may be aggravated by nonselective systemic beta blockade:

...it makes good sense to think selective



A bright outlook for glaucoma patients

For effective control of IOP
minimising the risks associated with
nonselective beta-blockade^{2,3,4}

T W I C E D A I L Y

Betoptic

OPHTHALMIC SOLUTION BETAXOLOL HCl

The only β_1 selective ocular beta blocker

BETA-BLOCKERS

PRESCRIBING INFORMATION: DOSAGE AND ADMINISTRATION:

Twice daily, one drop in the affected eye(s). In the event of a unilateral glaucoma, the other eye should be treated with a suitable ocular anticholinergic agent.

CONTRA-INDICATIONS:

Patients with a history of asthma or other respiratory disease, or with a history of heart failure, should not be treated with Betoptic.

WARNINGS AND PRECAUTIONS:

Patients with a history of asthma or other respiratory disease, or with a history of heart failure, should not be treated with Betoptic. Patients with a history of asthma or other respiratory disease, or with a history of heart failure, should not be treated with Betoptic. Patients with a history of asthma or other respiratory disease, or with a history of heart failure, should not be treated with Betoptic.

DRUG-INTERACTIONS:

Betoptic may interact with other drugs, particularly those which are known to affect the heart or the lungs. Patients should be advised to inform their doctor of all the drugs they are taking.

ADVERSE REACTIONS:

Adverse reactions to Betoptic are rare. However, patients should be advised to report any symptoms to their doctor, particularly if they experience difficulty in breathing or chest pain.

USE IN PREGNANCY:

Betoptic should not be used during pregnancy or while breastfeeding.

Some of the risks have not been fully identified and specific hazards are not always predictable and we recommend that patients should be monitored closely. **USE BY NURSING MOTHERS:** It is not known whether Betoptic is excreted in human milk. Caution should therefore be exercised when Betoptic is administered to nursing mothers. **TREATMENT OF OVERDOSE:** A toxic overdose of Betoptic may be treated with 100ml of 5% sodium bicarbonate solution. **BASIC NHS PRICE** £5.30 per 5ml dropper. **PRODUCT LICENCE HOLDER AND NUMBER:** Alcon Laboratories UK 0649/0097

REFERENCES:

1. *Eye* 1979; **3**: 117-118
2. *J Clin Pharm Ther* 1985; **10**: 27-30
3. *Surv Ophthalmol* 1984; **29**: 86-92
4. *Br J Ophthalmol* 1986; **70**: 1178-1184

For further information, contact your nearest Alcon representative.

Alcon

SPECIALISTS IN EYE CARE
Alcon Laboratories (UK) Ltd, Imperial Way, Watford, Herts WD2 4YR
Telephone: (0923) 246133 Fax: (0923) 243331
* Betoptic is a registered trademark of Alcon Laboratories